This inventor holds 2 USPTO granted patents, plus 1 CIPO patent. Top assignees: Kyoto University, Otsuka Pharmaceutical Factory, Inc.. Active years: 2012-2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2012-2013
Title: Hirofumi Noguchi: Innovator in Pancreatic Islet Isolation
Introduction
Hirofumi Noguchi is a notable inventor based in Kyoto, Japan. He has made significant contributions to the field of medical technology, particularly in the isolation of pancreatic islets. With a total of 2 patents, his work has the potential to impact diabetes treatment and research.
Latest Patents
Hirofumi Noguchi's latest patents focus on a method of separating pancreatic islets. The invention outlines a pancreatic islet isolation method that includes several key steps. First, a protection solution containing a protease inhibitor is injected into the pancreatic duct of a procured pancreas. Next, the pancreas is digested after the injection of the protection solution. Finally, the digested pancreatic tissue is purified using a purification solution that contains a density gradient reagent. This invention also includes a protection solution for injection into the pancreatic duct, a pancreas preservation solution for the two-layer method, and an islet purification solution.
Career Highlights
Throughout his career, Hirofumi Noguchi has worked with reputable organizations such as Otsuka Pharmaceutical Factory, Inc. and Kyoto University. His experience in these institutions has allowed him to develop and refine his innovative techniques in pancreatic islet isolation.
Collaborations
Hirofumi has collaborated with several professionals in his field, including Shinichi Matsumoto and Hiromi Wada. These collaborations have contributed to the advancement of his research and inventions.
Conclusion
Hirofumi Noguchi is a distinguished inventor whose work in pancreatic islet isolation holds promise for improving diabetes treatment. His innovative methods and collaborations reflect his commitment to advancing medical technology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

